As both ENaC [59] and ANO1 [60] are considered potential therapeutic targets in CF and there is a significant interest to develop drugs that modify the channel function, these channels could also be capitalized in the treatment of exocrine pancreatic diseases, such as CF-related exocrine pancreatic insufficiency, or chronic pancreatitis [61, 62]. Here, ANO1 is linked to cystic fibrosis.